Bristol-Myers gains U.S. antitrust clearance for $2.5 bln Inhibitex buy
Pharmaceutical giant Bristol-Myers Squibb has received U.S. antitrust approval for its acquisition of hepatitis C treatment maker Inhibitex, according to a company statement issued Friday. Washington – Pharmaceutical giant Bristol-Myers Squibb...To view the full article, register now.
Already a subscriber? Click here to view full article